COMMUNIQUÉS West-GlobeNewswire

-
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference
12/08/2025 -
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
12/08/2025 -
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
12/08/2025 -
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
12/08/2025 -
Phonak unveils Virto R Infinio: the compact rechargeable hearing aid designed for today's active lifestyle
12/08/2025 -
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
12/08/2025 -
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
12/08/2025 -
Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités
12/08/2025 -
iPETcertum™ by Claritas, Developed with Cutting-Edge Technology for Enhancement, Automated Segmentation and Accurate Quantification in PET, PET-CT/MRI Scans, Receives FDA Clearance
12/08/2025 -
Tecan reports solid financial results for the first half of 2025 and confirms its outlook for full year 2025
12/08/2025 -
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
12/08/2025 -
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
12/08/2025 -
Quipt Home Medical Reports Improved Fiscal Third Quarter 2025 Results
11/08/2025 -
Anteris Announces Results for the Second Quarter of 2025
11/08/2025 -
Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
11/08/2025 -
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
11/08/2025 -
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
11/08/2025 -
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
11/08/2025 -
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
11/08/2025
Pages